Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of ...
A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...
Longeveron Inc. a annoncé que, le 7 octobre 2026, la Dre Nataliya Agafonova a informé la direction de Longeveron Inc. de sa décision de quitter ses fonctions de directrice médicale, avec effet ...
Longeveron Inc. gab bekannt, dass Dr. Nataliya Agafonova das Management von Longeveron Inc. am 7. Oktober 2026 über ihre ...
Il 7 ottobre 2026, la dottoressa Nataliya Agafonova ha informato il management di Longeveron Inc. della decisione di lasciare l'incarico di direttrice medica, con effetto dal 14 ottobre ...
Longeveron Inc. announced that on October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, ...
New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Publishe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results